Neurosterix completes Phase 1 studies of NTX-253 for schizophrenia
Addex Therapeutics’ spin-out Neurosterix has completed Phase 1 clinical studies of NTX-253 for schizophrenia.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Neurosterix completes Phase 1 for NTX-253 in schizophrenia
Addex Therapeutics said its 20%-owned spin-out Neurosterix completed Phase 1 studies of NTX-253 and plans to advance it into Phase 2 for schizophrenia.